IFX group | Placebo group | All patients | |
---|---|---|---|
n = 18 | n = 17 | n = 35 | |
Age (years), median (IQR) | 45.0 (38.0–52.0) | 43.0 (40.0–48.0) | 44.0 (38.0–8.3) |
Male sex, n (%) | 11 (61.1) | 7 (41.2) | 18 (51.4) |
BMI (kg/m2), median (IQR) | 27.9 (24.8–29.8) | 25.8 (23.0–29.0) | 26.9 (24.4–29.8) |
Retired, n (%) | 0 (0) | 0 (0) | 0 (0) |
Sick leave, n (%) | 16 (88.9) | 15 (88.2) | 31 (88.6) |
Lumbar pain (VAS (0–100 mm)), median (IQR) | 60.0 (41.0–80.0) | 50.0 (26.0–60.0) | 58.0 (35.0–70.0) |
Radicular pain, (VAS (0–100 mm)), median (IQR) | 70.0 (65.0–85.0) | 55.0 (50.0–70.0) | 65.0 (45.0–76.0) |
Neuropathic pain, n (%) | 18 (100) | 11 (64.7) | 29 (82.9) |
Neuropathic pain (VAS (0–100 mm)), median (IQR) | 62.5 (40.0–75.0) | 45.0 (41.0–75.0) | 50.0 (41.0–70.0) |
Québec score (0–100), median (IQR) | 55.0 (37.0–68.0) | 45.0 (31.0–62.0) | 48.0 (37.0–63.0) |
HAD-S, median (IQR) | |||
HAD anxiety score (0–21) | 10.0 (6.0–15.0) | 10.0 (8.0–14.0) | 10.0 (6.0–14.0) |
HAD depression score (0–21) | 9.0 (6.0–11.0) | 7.0 (5.0–9.0) | 7.5 (6.0–11.0) |
FAB-Q, median (IQR) | |||
FAB-Q work subscale score (0–42) | 33.0 (21.0–41.0) | 24.0 (19.0–35.0) | 30.0 (20.0–39.0) |
FAB-Q physical activity subscale score (0–24) | 14.0 (11.0–19.0) | 16.0 (10.0–19.0) | 14.0 (10.0–20.0) |
Number of lumbar surgeries, n (%) | |||
1 | 9 (50.0) | 4 (23.5) | 13 (37.1) |
2 | 3 (16.7) | 9 (52.9) | 12 (34.3) |
3 | 4 (22.2) | 3 (17.7) | 7 (20.0) |
4 | 2 (11.1) | 1 (5.9) | 3 (8.6) |
Time between surgery and recurrent radicular pain (days), median (IQR) | 77.0 (46.0–142.0) | 99.0 (91.0–153.0) | 92.0 (61.0–153.0) |
Time between last surgery and inclusion (years), median (IQR) | 1.9 (1.4–3.0) | 2.7 (1.8–4.5) | 2.3 (1.6–3.6) |
Co-interventions, n (%) | 15 (83.3) | 15 (88.2) | 30 (85.7) |
Analgesics | 14 (77.8) | 15 (88.2) | 29 (82.9) |
Grade 1 | 9 (50.0) | 8 (47.1) | 17 (48.6) |
Grade 2 | 12 (66.7) | 11 (64.7) | 23 (65.7) |
Grade 3 | 2 (11.1) | 1 (5.9) | 3 (8.6) |
Nonsteroidal anti-inflammatory drugs | 5 (27.8) | 5 (29.4) | 10 (28.6) |
Corticosteroids | 2 (11.1) | 2 (11.8) | 4 (11.4) |
Antidepressants | 9 (50.0) | 11 (64.7) | 20 (57.1) |
Anxiolytics | 3 (16.7) | 3 (17.6) | 6 (17.1) |
Antiepileptics | 8 (44.4) | 8 (47.1) | 16 (45.7) |
Retractile scar, n (%) | 13 (72.2) | 10 (58.8) | 23 (65.7) |
Nerve root enhancement, n (%) | 14 (77.8) | 11 (64.7) | 25 (71.4) |
Nerve root enlargement, n (%) | 11 (61.1) | 4 (23.5) | 15 (42.9) |
Arachnoiditis, n (%) | 3 (16.7) | 2 (11.8) | 5 (14.3) |
Modic 1 changes, n (%) | 10 (55.6) | 9 (52.9) | 19 (54.3) |